The Change Mariner

Anti-obesity Breakthrough Lifts Alizyme

Financial Times (UK):

Shares in Alizyme rose more than 40 per cent on Friday after the drugs discovery group reported that its anti-obesity drug, the holy grail of pharmaceuticals, was not only as effective as its rivals but also caused fewer gastro-intestinal side effects.

Phase II drug trials showed that 90 per cent of 372 clinically obese patients tested over three months did not experience the uncomfortable side effects that existing treatments induce, including diarrhoea and incontinence.

Dr Richard Palmer, Alizyme's chief executive, hoped that this selling point will allow the product to compete with Roche's Xenical, now the only obesity drug available.

Amazon Price:

Amazon Price: